The growth in the historic period can be attributed to increasing prevalence of chronic hepatitis infections, widespread adoption of interferon-based therapies, established clinical efficacy of pegylated interferons, expansion of hospital-based antiviral treatments, availability of standardized treatment guidelines.
The growth in the forecast period can be attributed to declining use due to direct-acting antivirals, continued demand in specific patient populations, increasing focus on personalized hepatitis treatment, expansion of emerging market access programs, ongoing clinical research in oncology indications. Major trends in the forecast period include increasing focus on long-acting immunomodulatory therapies, rising preference for reduced-frequency dosing regimens, growing emphasis on combination antiviral treatment protocols, expansion of pegylation-based drug formulations, enhanced monitoring of treatment outcomes.
The increasing prevalence of hepatitis B is expected to drive the growth of the Pegasys market. Hepatitis B is a viral infection that attacks the liver, potentially leading to chronic disease, cirrhosis, and liver cancer. The rise in hepatitis B cases is influenced by factors such as increased transmission through unprotected sex, intravenous drug use, and insufficient vaccination coverage in certain regions. Pegasys is used to treat hepatitis B by enhancing the immune response to control viral replication and reduce liver damage. For example, in April 2024, the European Centre for Disease Prevention and Control, a Sweden-based government health agency, reported 28,855 recorded cases of hepatitis B virus (HBV) infection across 30 EU/EEA Member States in 2022, marking a 78% increase from 16,187 cases the previous year. Additionally, the total number of cases in 2022, 28,420, represents a crude rate of 8.5 cases per 100,000 population. As a result, the growing prevalence of hepatitis B worldwide is expected to significantly fuel the growth of the Pegasys market.
The growing healthcare expenditure is projected to further drive the growth of the Pegasys market. Healthcare spending refers to the financial investments made by governments, private sectors, and organizations to support medical services, infrastructure, and public health initiatives. The increase in global healthcare expenditure is driven by factors such as the rising prevalence of infectious diseases, the need to strengthen healthcare systems, and a commitment to improving public health outcomes. The rise in healthcare expenditure supports the growth of Pegasys by enabling more significant investment in antiviral treatments, improving patient access to hepatitis therapies, and increasing funding for advanced biologic medicines. For example, in May 2024, the Office for National Statistics, a UK-based authority, reported that UK healthcare expenditure reached around $359.16 billion (£292 billion) in 2023, with total healthcare spending increasing by 5.6% in nominal terms. Additionally, in 2022, total long-term health and social care expenditure grew by 2.8% in real terms. As a result, rising healthcare expenditure is expected to accelerate the growth of the Pegasys market.
A key trend in the Pegasys market is the expansion of its use beyond its initial indications to include treatments for conditions like polycythemia vera (PV) and essential thrombocythemia (ET), aiming to enhance its market presence and patient reach in the oncology and hematology sectors. Pegasys helps regulate abnormal blood cell production in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET) as part of its expanded application for managing myeloproliferative neoplasms. For example, in July 2024, pharmaand GmbH (pharma&) received approval from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for a Type II variation for Pegasys (peginterferon alfa-2a) as a treatment for all eligible patients with polycythemia vera (PV) or essential thrombocythemia (ET). Pegasys is currently approved by the EMA for the treatment of chronic hepatitis B (CHB) in adults and children aged 3 years and older, as well as chronic hepatitis C (CHC) in adults and children aged 5 years and older, in combination with other medications. However, Pegasys has seen expanded use following its inclusion in independently developed oncology guidelines for myeloproliferative neoplasms (MPNs), PV, and ET.
Major companies operating in the pegasys market are Roche Holding AG, pharmaand GmbH.
North America was the largest region in the pegasys market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pegasys market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pegasys market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are impacting the Pegasys market by increasing costs associated with imported active pharmaceutical ingredients, specialized pegylation materials, prefilled syringes, and cold-chain packaging components used in biologic drug manufacturing. North America and Europe are most affected due to reliance on global biologics supply chains, while Asia-Pacific faces pricing pressure on export-oriented pharmaceutical production. These tariffs contribute to higher treatment costs and supply chain complexity for hospitals and pharmacies. However, they are also encouraging localized biologics manufacturing, regional API sourcing, and investments in domestic biopharmaceutical production capabilities.
The pegasys market research report is one of a series of new reports that provides pegasys market statistics, including pegasys industry global market size, regional shares, competitors with a pegasys market share, detailed pegasys market segments, market trends and opportunities, and any further data you may need to thrive in the pegasys industry. This pegasys market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Pegasys is a brand of pegylated interferon alfa-2a used to treat chronic hepatitis B and C, as well as specific types of cancer, including chronic myelogenous leukemia and malignant melanoma. It works by enhancing the body's immune response to fight viral infections and cancer cells. Typically administered via subcutaneous injection, pegylation extends its half-life, allowing for less frequent dosing compared to non-pegylated interferons.
The primary indications for Pegasys include chronic hepatitis C and chronic hepatitis B. Chronic hepatitis C is a long-term liver infection caused by the hepatitis C virus (HCV), which can result in severe liver damage, cirrhosis, or liver cancer if untreated. Pegasys is used as part of a treatment regimen to manage chronic hepatitis C by strengthening the immune response to combat the virus. Distribution channels for Pegasys include hospital pharmacies, retail pharmacies, and online pharmacies, serving end users such as hospitals, clinics, ambulatory care settings, and home care.
The pegasys market consists of sales of monovalent and combination formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The growth in the forecast period can be attributed to declining use due to direct-acting antivirals, continued demand in specific patient populations, increasing focus on personalized hepatitis treatment, expansion of emerging market access programs, ongoing clinical research in oncology indications. Major trends in the forecast period include increasing focus on long-acting immunomodulatory therapies, rising preference for reduced-frequency dosing regimens, growing emphasis on combination antiviral treatment protocols, expansion of pegylation-based drug formulations, enhanced monitoring of treatment outcomes.
The increasing prevalence of hepatitis B is expected to drive the growth of the Pegasys market. Hepatitis B is a viral infection that attacks the liver, potentially leading to chronic disease, cirrhosis, and liver cancer. The rise in hepatitis B cases is influenced by factors such as increased transmission through unprotected sex, intravenous drug use, and insufficient vaccination coverage in certain regions. Pegasys is used to treat hepatitis B by enhancing the immune response to control viral replication and reduce liver damage. For example, in April 2024, the European Centre for Disease Prevention and Control, a Sweden-based government health agency, reported 28,855 recorded cases of hepatitis B virus (HBV) infection across 30 EU/EEA Member States in 2022, marking a 78% increase from 16,187 cases the previous year. Additionally, the total number of cases in 2022, 28,420, represents a crude rate of 8.5 cases per 100,000 population. As a result, the growing prevalence of hepatitis B worldwide is expected to significantly fuel the growth of the Pegasys market.
The growing healthcare expenditure is projected to further drive the growth of the Pegasys market. Healthcare spending refers to the financial investments made by governments, private sectors, and organizations to support medical services, infrastructure, and public health initiatives. The increase in global healthcare expenditure is driven by factors such as the rising prevalence of infectious diseases, the need to strengthen healthcare systems, and a commitment to improving public health outcomes. The rise in healthcare expenditure supports the growth of Pegasys by enabling more significant investment in antiviral treatments, improving patient access to hepatitis therapies, and increasing funding for advanced biologic medicines. For example, in May 2024, the Office for National Statistics, a UK-based authority, reported that UK healthcare expenditure reached around $359.16 billion (£292 billion) in 2023, with total healthcare spending increasing by 5.6% in nominal terms. Additionally, in 2022, total long-term health and social care expenditure grew by 2.8% in real terms. As a result, rising healthcare expenditure is expected to accelerate the growth of the Pegasys market.
A key trend in the Pegasys market is the expansion of its use beyond its initial indications to include treatments for conditions like polycythemia vera (PV) and essential thrombocythemia (ET), aiming to enhance its market presence and patient reach in the oncology and hematology sectors. Pegasys helps regulate abnormal blood cell production in the treatment of polycythemia vera (PV) and essential thrombocythemia (ET) as part of its expanded application for managing myeloproliferative neoplasms. For example, in July 2024, pharmaand GmbH (pharma&) received approval from the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) for a Type II variation for Pegasys (peginterferon alfa-2a) as a treatment for all eligible patients with polycythemia vera (PV) or essential thrombocythemia (ET). Pegasys is currently approved by the EMA for the treatment of chronic hepatitis B (CHB) in adults and children aged 3 years and older, as well as chronic hepatitis C (CHC) in adults and children aged 5 years and older, in combination with other medications. However, Pegasys has seen expanded use following its inclusion in independently developed oncology guidelines for myeloproliferative neoplasms (MPNs), PV, and ET.
Major companies operating in the pegasys market are Roche Holding AG, pharmaand GmbH.
North America was the largest region in the pegasys market in 2025. Asia Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the pegasys market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the pegasys market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.
Tariffs are impacting the Pegasys market by increasing costs associated with imported active pharmaceutical ingredients, specialized pegylation materials, prefilled syringes, and cold-chain packaging components used in biologic drug manufacturing. North America and Europe are most affected due to reliance on global biologics supply chains, while Asia-Pacific faces pricing pressure on export-oriented pharmaceutical production. These tariffs contribute to higher treatment costs and supply chain complexity for hospitals and pharmacies. However, they are also encouraging localized biologics manufacturing, regional API sourcing, and investments in domestic biopharmaceutical production capabilities.
The pegasys market research report is one of a series of new reports that provides pegasys market statistics, including pegasys industry global market size, regional shares, competitors with a pegasys market share, detailed pegasys market segments, market trends and opportunities, and any further data you may need to thrive in the pegasys industry. This pegasys market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
Pegasys is a brand of pegylated interferon alfa-2a used to treat chronic hepatitis B and C, as well as specific types of cancer, including chronic myelogenous leukemia and malignant melanoma. It works by enhancing the body's immune response to fight viral infections and cancer cells. Typically administered via subcutaneous injection, pegylation extends its half-life, allowing for less frequent dosing compared to non-pegylated interferons.
The primary indications for Pegasys include chronic hepatitis C and chronic hepatitis B. Chronic hepatitis C is a long-term liver infection caused by the hepatitis C virus (HCV), which can result in severe liver damage, cirrhosis, or liver cancer if untreated. Pegasys is used as part of a treatment regimen to manage chronic hepatitis C by strengthening the immune response to combat the virus. Distribution channels for Pegasys include hospital pharmacies, retail pharmacies, and online pharmacies, serving end users such as hospitals, clinics, ambulatory care settings, and home care.
The pegasys market consists of sales of monovalent and combination formulations. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. Pegasys Market Characteristics
3. Pegasys Market Supply Chain Analysis
4. Global Pegasys Market Trends and Strategies
5. Pegasys Market Analysis of End Use Industries
7. Global Pegasys Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global Pegasys Total Addressable Market (TAM) Analysis for the Market
9. Pegasys Market Segmentation
10. Pegasys Market Regional and Country Analysis
11. Asia-Pacific Pegasys Market
12. China Pegasys Market
13. India Pegasys Market
14. Japan Pegasys Market
15. Australia Pegasys Market
16. South Korea Pegasys Market
17. Western Europe Pegasys Market
18. UK Pegasys Market
19. Germany Pegasys Market
20. France Pegasys Market
21. Eastern Europe Pegasys Market
22. North America Pegasys Market
23. USA Pegasys Market
24. Canada Pegasys Market
25. South America Pegasys Market
26. Middle East Pegasys Market
27. Africa Pegasys Market
29. Pegasys Market Competitive Landscape and Company Profiles
32. Pegasys Market High Potential Countries, Segments and Strategies
33. Appendix
Executive Summary
Pegasys Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses pegasys market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for pegasys? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The pegasys market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Indication: Chronic Hepatitis C; Chronic Hepatitis B2) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
3) By End-Users: Hospitals; Clinics; Ambulatory Care; Home Care
Companies Mentioned: Roche Holding AG; pharmaand GmbH
Countries: Australia; India; China; South Korea; Japan; UK; France; Germany; USA; Canada.
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this Pegasys market report include:- Roche Holding AG
- pharmaand GmbH
